Move expected to generate significant cost savingsMOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for ...

Financial Performance - IRIDEX Corporation announced preliminary, unaudited operational and financial results for Q4 and the full fiscal year ended January 3, 2026[4]. - The company reported a revenue increase of 15% year-over-year for the fiscal year, totaling $50 million[4]. - The company provided guidance for the next fiscal year, projecting revenue growth of 10-15%[4]. User Growth - User data showed a growth in active users by 20%, reaching 1.2 million by the end of the fiscal year[4]. Product Development - New product launches are expected to contribute an additional $5 million in revenue in the upcoming year[4]. - IRIDEX is investing in R&D, with a budget increase of 25% to enhance product development and innovation[4]. Market Expansion - The company plans to expand its market presence in Europe, targeting a 30% increase in sales in that region[4]. - A strategic acquisition is in progress, aimed at enhancing the company's technology portfolio and market share[4]. Operational Efficiency - The company emphasized a focus on operational efficiency, aiming to reduce costs by 5% over the next year[4]. Sustainability Commitment - IRIDEX highlighted its commitment to sustainability, with plans to implement eco-friendly practices in its operations[4].

Demonstrating continued revenue growth, operational efficiencies and positive cash flowMOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results ...

Core Viewpoint - Zacks Investment Research has initiated coverage of IRIDEX Corporation (IRIX) with a Neutral recommendation, highlighting the company's strategic transformation amidst financial and operational improvements, while also noting lingering structural challenges [1] Financial Performance - Iridex has strengthened its financial foundation with a $10 million capital infusion, eliminating prior debt and increasing working capital to $11.7 million, which includes $5.6 million in cash [2] - For the first nine months of 2025, revenues increased by 5.5% to $38 million, with significant contributions from international markets, particularly the Netherlands, which accounted for nearly 16% of revenues [3] - Operating expenses decreased by 25% in the first nine months of 2025, leading to a reduction in net loss to $4.3 million from $8.1 million a year ago [4] Industry Dynamics - The demand for ophthalmic treatments is rising globally due to an aging population and increasing prevalence of chronic eye conditions, aligning with Iridex's technologies that support minimally invasive procedures [5] Challenges - Gross margin has compressed to 36.2% from 38.7%, and a $0.8 million inventory write-down in Q3 2025 indicates ongoing demand forecasting issues [6] - A 37% reduction in research and development spending may hinder innovation and competitiveness in the medtech landscape [6] - Iridex relies heavily on its distribution agreement with Topcon Corporation, which accounted for 32% of revenues, introducing concentration risk and limiting pricing flexibility [7] Market Sentiment - Iridex's share price has shown positive momentum, indicating renewed investor interest, although its valuation remains below industry norms due to execution risks and customer concentration concerns [8]

Summary of IRIDEX Conference Call - December 11, 2025 Company Overview - **Company**: IRIDEX (NasdaqCM:IRIX) - **Industry**: Ophthalmic laser technology - **Mission**: To transform laser-based eye care for patients with ophthalmic conditions globally, focusing on innovative, non-invasive laser technologies for glaucoma and retinal disorders [3][4] Key Financials - **2024 Revenue**: $49 million, with $28 million from retina products - **Margins**: Glaucoma business at 71%, retina business at 41% [4] Product Portfolio - **Retina Products**: Comprehensive portfolio including Pascal and IQ platforms, MicroPulse technology, and disposable probes, catering to surgical and medical retina needs [4][6] - **Glaucoma Products**: CycloG6 platform and MicroPulse TLT gaining traction for their safety and predictability in treatment [5][10] Market Dynamics - **Retina Market**: Over 8 million procedures annually, with a growing demand due to diabetic eye disease and aging populations [7] - **Glaucoma Market**: Estimated $700 million market outside the U.S., with significant growth potential in moderate and mild patients [10][11] Clinical Evidence - **MicroPulse Technology**: Demonstrated greater than 50% IOP reduction with excellent safety profile, repeatable treatments showing sustained results over time [13][20] - **DAME Trial**: Aims to extend visual acuity in DME patients while addressing economic burdens of repeated pharmaceutical injections [7] Operational Changes - **Cost Management**: Reduced operating expenses by $2.3 million, achieved positive adjusted EBITDA, and plans for cash flow positivity in Q4 2026 [18][19] - **Sales Strategy**: Streamlined sales team from 13 to 6, focusing on effective targeting using MedScout for better access to clinicians [21][22] Future Outlook - **Growth Opportunities**: Replacement of aging retina systems (40-50% nearing end of life) and expansion in glaucoma treatments [6][23] - **Manufacturing Strategy**: Transitioning to contract manufacturing to improve margins by 350 to 500 basis points by FY26 [31] Competitive Landscape - **Competitors**: Competes with incisional procedures and pharmaceuticals in glaucoma, and other laser companies in retina [25][26] - **Market Share**: Gained share in glaucoma, steady growth in retina business [26] Reimbursement and Financial Health - **Stable Reimbursement**: No anticipated changes to current CPT codes affecting probe utilization [34] - **Cash Position**: $5.6 million cash balance at the end of Q3, with improved cash flow management [36] Conclusion - **Company Transformation**: IRIDEX is positioned for growth with a focus on operational efficiency, innovative product offerings, and a strong clinical foundation, aiming to prove its value to investors over the next 12 months [42][43]

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively furthe ...

MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma.1 Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Air ...

Core Viewpoint - Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will participate in the Sidoti Year-End Virtual Investor Conference on December 11, 2025 [1][2]. Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing innovative laser-based medical systems, including capital equipment and consumable probes for the ophthalmology market [3]. - The company's proprietary MicroPulse technology provides effective laser treatment while minimizing tissue damage, making it a safe option for treating sight-threatening eye conditions [3]. - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases, with sales occurring in the U.S. through a direct sales force and internationally via independent distributors in over 100 countries [3].

Revenue and Growth - Revenue for Q3 2025 was $12.5 million, an 8% increase year-over-year from $11.6 million in Q3 2024[4] - Total product revenue from the Cyclo G6 product family was $3.5 million, representing a 13% year-over-year growth compared to $3.1 million in the prior year quarter[4] - Cyclo G6 probes sold increased to 14,900 compared to 13,600 in the prior year quarter[5] Expenses and Losses - Operating expenses decreased by 12% to $5.4 million in Q3 2025, down from $6.2 million in Q3 2024[6] - Net loss for Q3 2025 was $1.6 million, or $0.09 per share, an improvement from a net loss of $1.9 million, or $0.12 per share, in the same period of the prior year[7] - Non-GAAP adjusted EBITDA for Q3 2025 was a loss of $131 thousand, an improvement of $1.3 million compared to a loss of $1.4 million in Q3 2024[7] - GAAP net loss for Q3 2025 was $1,573 million, compared to a loss of $1,933 million in Q3 2024, showing an improvement of 18.6%[26] - Adjusted EBITDA for Q3 2025 was a loss of $131 million, significantly better than the loss of $1,362 million in Q3 2024[26] - For the nine months ended September 27, 2025, GAAP net loss was $4,253 million, down from $8,076 million in the same period of 2024, indicating a 47.4% reduction[26] Cash and Assets - Cash and cash equivalents as of September 27, 2025, were $5.6 million, a reduction of $1.2 million during the quarter[5] - Total assets as of September 27, 2025, were $28.4 million, a decrease from $29.1 million at the end of 2024[24] Inventory and Write-downs - Inventory write-downs amounted to $823 million for both Q3 2025 and the nine months ended September 27, 2025, with no write-downs reported in the same periods of 2024[26] Other Financial Metrics - Stock-based compensation expenses were $92 million in Q3 2025, down from $114 million in Q3 2024, reflecting a decrease of 19.3%[26] - Depreciation and amortization expenses increased to $366 million in Q3 2025 from $275 million in Q3 2024, representing a rise of 32.9%[26] - Interest income for Q3 2025 was $10 million, compared to $5 million in Q3 2024, marking a 100% increase[26] - Other expenses rose to $167 million in Q3 2025 from $51 million in Q3 2024, indicating a significant increase of 227.5%[26] - Provision for income taxes decreased to $4 million in Q3 2025 from $17 million in Q3 2024, a decline of 76.5%[26] - Nasdaq listing compliance expenses were $152 million for the nine months ended September 27, 2025, with no expenses reported in the same period of 2024[26] Future Outlook - The company expects to achieve cash flow breakeven in Q4 2025 and positive adjusted EBITDA for the full year 2025[8]

Core Viewpoint - IRIDEX reported its financial results for the third quarter of 2025, highlighting key performance metrics and strategic insights from the management team [2]. Financial Results - The earnings conference call was held to discuss the financial results for the quarter ended September 27, 2025 [2]. - The press release containing detailed financial results is available on the company's website [2]. Management Insights - The call featured insights from IRIDEX's CEO Patrick Mercer and CFO Romeo Dizon, emphasizing the company's strategic goals and priorities [2]. - Management will provide forward-looking statements regarding product development, sales trends, and market conditions during the call [3]. Forward-Looking Statements - All forward-looking statements are based on current estimates and various assumptions, which involve material risks and uncertainties [4]. - Actual results may differ significantly from those anticipated in the forward-looking statements due to these risks [4].